83 related articles for article (PubMed ID: 25399009)
1. Phosphorylation sites of HER2/c-erbB-2: role in cell growth and in disease.
Khurshid R; Saleem M; Gul-e-Raana ; Akhthar MS
Acta Biochim Pol; 2014; 61(4):699-703. PubMed ID: 25399009
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
3. Atomistic insights into regulatory mechanisms of the HER2 tyrosine kinase domain: a molecular dynamics study.
Telesco SE; Radhakrishnan R
Biophys J; 2009 Mar; 96(6):2321-34. PubMed ID: 19289058
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
5. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
7. The ErbB/HER receptor protein-tyrosine kinases and cancer.
Roskoski R
Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
[TBL] [Abstract][Full Text] [Related]
8. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors.
Brignola PS; Lackey K; Kadwell SH; Hoffman C; Horne E; Carter HL; Stuart JD; Blackburn K; Moyer MB; Alligood KJ; Knight WB; Wood ER
J Biol Chem; 2002 Jan; 277(2):1576-85. PubMed ID: 11696537
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.
Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP
Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535
[TBL] [Abstract][Full Text] [Related]
11. Preferential detection of catalytically inactive c-erbB-2 by antibodies to unphosphorylated peptides mimicking receptor tyrosine autophosphorylation sites.
Epstein RJ
Oncogene; 1995 Jul; 11(2):315-23. PubMed ID: 7624146
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases.
Singh J; Dobrusin EM; Fry DW; Haske T; Whitty A; McNamara DJ
J Med Chem; 1997 Mar; 40(7):1130-5. PubMed ID: 9089334
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
14. Structural features that specify tyrosine kinase activity deduced from homology modeling of the epidermal growth factor receptor.
Knighton DR; Cadena DL; Zheng J; Ten Eyck LF; Taylor SS; Sowadski JM; Gill GN
Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5001-5. PubMed ID: 8389462
[TBL] [Abstract][Full Text] [Related]
15. Calmodulin binds HER2 and modulates HER2 signaling.
White CD; Li Z; Sacks DB
Biochim Biophys Acta; 2011 May; 1813(5):1074-82. PubMed ID: 21185879
[TBL] [Abstract][Full Text] [Related]
16. EGFR kinase possesses a broad specificity for ErbB phosphorylation sites, and ligand increases catalytic-centre activity without affecting substrate binding affinity.
Fan YX; Wong L; Johnson GR
Biochem J; 2005 Dec; 392(Pt 3):417-23. PubMed ID: 16122376
[TBL] [Abstract][Full Text] [Related]
17. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR.
Dittmar T; Husemann A; Schewe Y; Nofer JR; Niggemann B; Zänker KS; Brandt BH
FASEB J; 2002 Nov; 16(13):1823-5. PubMed ID: 12354693
[TBL] [Abstract][Full Text] [Related]
18. Application of Immunofluorescence Staining to Study ErbB Family of Receptor Tyrosine Kinases.
Nami B; Wang Z
Methods Mol Biol; 2017; 1652():109-116. PubMed ID: 28791637
[TBL] [Abstract][Full Text] [Related]
19. Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases.
Shih AJ; Telesco SE; Choi SH; Lemmon MA; Radhakrishnan R
Biochem J; 2011 Jun; 436(2):241-51. PubMed ID: 21426301
[TBL] [Abstract][Full Text] [Related]
20. Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains.
Murali R; Brennan PJ; Kieber-Emmons T; Greene MI
Proc Natl Acad Sci U S A; 1996 Jun; 93(13):6252-7. PubMed ID: 8692801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
